Evidence map›Paper›PMID 36045933›Full record

ArticleJournal of neurosurgery. Case lessons2021

Cerebellar high-grade glioma with H3 K27M mutation: illustrative case.

Mikiko Takahashi, Yusuke Tomita, Shoko Merrit Yamada, Kazuto Yamazaki, Hideaki Yokoo, Tatsuya Aso, Masashi Kawamoto

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Journal of neurosurgery. Case lessons, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mikiko TakahashiDepartments of Diagnostic Pathology and.
Yusuke TomitaNeurosurgery, Teikyo University Hospital, Mizonokuchi, Kawasaki, Kanagawa, Japan.
Shoko Merrit YamadaNeurosurgery, Teikyo University Hospital, Mizonokuchi, Kawasaki, Kanagawa, Japan.
Kazuto YamazakiDepartment of Pathology, Teikyo University Chiba Medical Center, Ichihara, Chiba, Japan; and.
Hideaki YokooDepartment of Human Pathology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Tatsuya AsoDepartments of Diagnostic Pathology and.
Masashi KawamotoDepartments of Diagnostic Pathology and.
Teikyo University · JPGunma University · JPTeikyo University Chiba Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiffuse midline glioma H3 K27M-mutant is a distinct subtype of glial tumors newly introduced in the revised fourth edition of the World Health Organization OBSERVATIONS: The authors present the case of a man in his 60s who presented with rotatory vertigo, taste disorder, and right facial paralysis. Magnetic resonance imaging showed a tumor expanding from the cerebellum to the pons, which was histologically identified as glioblastoma, grade IV, IDH wild type. After tumor resection, the patient received chemoradiotherapy but showed only a partial response. His condition gradually worsened, and he died of progressive disease 12 months postoperation, after which an autopsy was performed. Tumor cells with a high nuclear-to-cytoplasm ratio were immunohistochemically analyzed and found to test positive for H3 K27M and negative for H3 K27me3. Furthermore, mutational analysis revealed LESSONS: When a glioblastoma shows localization or dissemination patterns different from those of typical glioblastoma, an H3 K27M-mutant glioma should be suspected.

Indexed as

adultcerebellumdisseminationH3 K27M mutationhigh-grade gliomaMRI = magnetic resonance imagingWHO = World Health Organization

Identifiers

PMID36045933
PMCPMC9394179
OpenAlexW3135266668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.